Practical management of patients with myelofibrosis receiving ruxolitinib

@article{Harrison2013PracticalMO,
  title={Practical management of patients with myelofibrosis receiving ruxolitinib},
  author={Claire N Harrison and Ruben A Mesa and David M. Ross and Adam J. Mead and Clodagh Keohane and Jason Gotlib and Srdan Verstovsek},
  journal={Expert Review of Hematology},
  year={2013},
  volume={6},
  pages={511 - 523}
}
Myelofibrosis (MF) is characterized by bone marrow fibrosis, progressive anemia and extramedullary hematopoiesis, primarily manifested as splenomegaly. Patients also experience debilitating constitutional symptoms, including sequelae of splenomegaly, night sweats and fatigue. Ruxolitinib (INC424, INCB18424, Jakafi, Jakavi), a JAK1 and JAK2 inhibitor, was approved in November 2011 by the US FDA for the treatment of intermediate- or high-risk MF, and more recently in Europe and Canada for the… 
Managing patients with myelofibrosis and low platelet counts
TLDR
The prevalence, prognostic implications, and management of thrombocytopenia in MF and the different therapeutic options available for this patient population are discussed, with an emphasis on current clinical experience with targeted therapies, as well as recent findings from several clinical studies currently underway.
Practical management of myelofibrosis with ruxolitinib
TLDR
This article presents recommendations for the practical management of myelofibrosis with ruxolitinib, a selective inhibitor of both JAK1 and JAK2, and its role in special subgroups of patients, such as those undergoing stem cell transplantation and those experiencing thrombosis as a major manifestation of the myel ofibrosis.
Recommendations on the use of ruxolitinib for the treatment of myelofibrosis
TLDR
The Belgian regulation for ruxolitinib should be revised in terms of reimbursement criteria, dose titration, stopping rules, and patient follow-up to optimize the treatment of MF patients.
Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations
TLDR
The panel does not recommend ruxolitinib therapy for improving survival, but was strongly recommended for improving symptomatic or severe splenomegaly in patients with an International Prognostic Scoring System (IPSS) risk intermediate 2 or high.
The use of erythropoiesis-stimulating agents with ruxolitinib in patients with myelofibrosis in COMFORT-II: an open-label, phase 3 study assessing efficacy and safety of ruxolitinib versus best available therapy in the treatment of myelofibrosis
TLDR
This post hoc analysis evaluated the safety and efficacy of concomitant ruxolitinib and ESA administration in patients enrolled in COMFORT-II, an open-label, phase 3 study comparing the efficacy and safety of ruxolinib with best available therapy for treatment of myelofibrosis.
Persistence of myelofibrosis treated with ruxolitinib: biology and clinical implications
TLDR
What is known about pathological JAK-STAT activation in myel ofibrosis and how this might lead to future novel therapies for myelofibrosis with greater disease-modifying potential are summarized.
Varicella Zoster Infection Associated withPharmacological JAK-STAT Inhibition viaRuxolitinib in Myeloproliferative Diseases
TLDR
The first cases with cutaneous manifestations of VZV infections are described, who receiving Ruxolitinib therapy for MPD, other than the process of bone marrow transplantation.
Targeting megakaryocytic-induced fibrosis in myeloproliferative neoplasms by AURKA inhibition
TLDR
It is suggested that megakaryocytes drive fibrosis in PMF and that targeting them with AURKA inhibitors has the potential to provide therapeutic benefit, and heterozygous deletion of Aurka was sufficient to ameliorate fibrosis and other PMF features in vivo.
Targeting megakaryocytic induced fibrosis by AURKA inhibition in the myeloproliferative neoplasms
Primary myelofibrosis (PMF) is characterized by bone marrow fibrosis, myeloproliferation, extramedullary hematopoiesis, splenomegaly and leukemic progression. Moreover, the bone marrow and spleen of
Chapter 17 – Ruxolitinib
TLDR
The safety profile is characterized by myelosuppression, mainly expressed as thrombocytopenia, anemia, and neutropenia; and nonhematologic events, such as cephalea, dizziness, and bruising.
...
1
2
3
4
...

References

SHOWING 1-10 OF 71 REFERENCES
How I treat symptomatic splenomegaly in patients with myelofibrosis.
TLDR
Future care of MF patients, including splenomegaly management, will continue to require the hematologist to select therapeutic options carefully in the context of realistic, achievable goals.
Serious adverse events during ruxolitinib treatment discontinuation in patients with myelofibrosis.
TLDR
The sponsor-independent analysis describes the details of these events in 5 severely affected cases among 47 Mayo Clinic patients with MF in whom ruxolitinib therapy had been discontinued, characterized by acute relapse of disease symptoms, accelerated splenomegaly, worsening of cytopenias, and occasional hemodynamic decompensation, including a septic shocklike syndrome.
Therapy for the Treatment of Myelofibrosis
The BCR-ABL1-negative myeloproliferative neoplasms (essential thrombocythemia, polycythemia vera, and primary myelofibrosis) are a group of heterogeneous hematologic malignancies involving a clonal
How I treat splenomegaly in myelofibrosis
TLDR
A new class of drugs, the JAK2 inhibitors, although also palliative, are promising in the splenomegaly of MF and will probably change the therapeutic algorithm of this disease.
The Use of Erythropoietic-Stimulating Agents (ESAs) with Ruxolitinib in Patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (PPV-MF), and Post-Essential Thrombocythemia Myelofibrosis (PET-MF).
TLDR
Rux was generally well tolerated in pts who received ESA, and the tolerability profile of rux was similar to that reported in previous studies, suggesting that the use of ESA in combination with rUX was beneficial in some pts.
Ruxolitinib Provides Reductions in Splenomegaly Across Subgroups: An Analysis of Spleen Response in the COMFORT-II Study
TLDR
Ruxolitinib was shown to be more effective than BAT at reducing spleen volume in all patient subgroups regardless of gender, age, mutation status, IPSS risk category, baseline spleen size, MF subtype, or ruxolit inib starting dose.
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
TLDR
Continuous ruxolitinib therapy, as compared with the best available therapy, was associated with marked and durable reductions in splenomegaly and disease-related symptoms, improvements in role functioning and quality of life, and modest toxic effects.
Therapeutic Potential of Janus-activated Kinase-2 Inhibitors for the Management of Myelofibrosis
TLDR
The origins of the JAK2 hypothesis, the clinical relevance of Jak2 mutations in myelofibrosis, and recent clinical progress in targeting JAKs as a therapeutic intervention for patients with this chronic and debilitating disease are discussed.
Myelofibrosis with myeloid metaplasia: disease overview and non-transplant treatment options.
TLDR
This chapter reviews both the old and the new therapy with regard to non-transplant treatment options for MMM, where modern therapy remains palliative but allogeneic stem cell transplantation might be curative to a selected group of patients.
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
TLDR
Ruxolitinib provided significant clinical benefits in patients with myel ofibrosis by reducing spleen size, ameliorating debilitating myelofibrosis-related symptoms, and improving overall survival.
...
1
2
3
4
5
...